Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM79VXT)

Drug Name
PF-04971729 Drug Info
Synonyms
Ertugliflozin; 1210344-57-2; PF04971729; UNII-6C282481IP; PF 04971729; CHEMBL1770248; 6C282481IP; AK174928; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; Steglatro; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; Ertugliflozin [USAN:INN]; C22H25ClO7; PF-4971729; SGLT2 inhibitor (oral, type 2 diabetes), Pfizer; Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer; Ertugliflozin/PF-04971729
Cross-matching ID
PubChem CID
44814423
ChEBI ID
CHEMBL1770248
CAS Number
CAS 1210344-57-2
TTD Drug ID
D0Q3VE
INTEDE Drug ID
DR0604
ACDINA Drug ID
D00240

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.16 0.00e+0 19/20 (95%) SQLE;DHCR24;LSS;...
Inflammatory bowel disease -1.61 4.64e-2 58/65 (89.23%) STAT4;IL23A;TLR5;...
Histidine metabolism -1.61 4.69e-2 16/22 (72.73%) CNDP2;ASPA;AOC1;...
Glutathione metabolism -1.61 4.87e-2 43/57 (75.44%) GSTA4;IDH2;GSTA1;...
Leishmaniasis -1.61 4.90e-2 67/77 (87.01%) ELK1;TRAF6;HLA-DQB1;...
N-Glycan biosynthesis -1.62 4.50e-2 38/50 (76%) MAN1B1;ALG13;B4GALT2;...
Steroid hormone biosynthesis -1.64 3.89e-2 43/61 (70.49%) UGT2B4;CYP2E1;CYP1B1;...
Metabolism of xenobiotics by cytochrome P450 -1.65 3.42e-2 49/77 (63.64%) UGT2B4;CYP2E1;CYP2C9;...
Ascorbate and aldarate metabolism -1.66 3.38e-2 15/30 (50%) UGT2B4;RGN;UGT2B17;...
Arachidonic acid metabolism -1.66 3.50e-2 48/61 (78.69%) HPGDS;GGT1;ALOX12B;...
Amino sugar and nucleotide sugar metabolism -1.66 3.52e-2 38/48 (79.17%) GALK1;NPL;GMDS;...
Staphylococcus aureus infection -1.66 3.73e-2 72/95 (75.79%) HLA-DQB1;CAMP;KRT17;...
Glycolysis / Gluconeogenesis -1.67 3.63e-2 56/67 (83.58%) HKDC1;HK1;PGK1;...
Pentose and glucuronate interconversions -1.67 3.87e-2 17/34 (50%) UGT2B17;UGT2A3;CRYL1;...
Linoleic acid metabolism -1.72 2.49e-2 21/29 (72.41%) CYP2C8;PLA2G1B;PLA2G10;...
Cell adhesion molecules -1.78 1.46e-2 118/148 (79.73%) CDH3;HLA-F;HLA-DOA;...
Pentose phosphate pathway -1.79 1.23e-2 25/30 (83.33%) PGLS;RGN;ALDOA;...
Phagosome -1.83 1.15e-2 118/152 (77.63%) ATP6V1B1;FCGR2B;HLA-F;...
Glycine, serine and threonine metabolism -1.83 1.16e-2 31/40 (77.5%) SRR;SHMT2;ALDH7A1;...
Arginine and proline metabolism -1.86 8.21e-3 39/50 (78%) ODC1;PRODH2;P4HA1;...
Asthma -1.87 9.24e-3 25/31 (80.65%) HLA-DQB1;HLA-DQA1;HLA-DPB1;...
Graft-versus-host disease -1.91 3.02e-3 32/42 (76.19%) HLA-E;KIR2DL1;HLA-F;...
Viral myocarditis -1.92 3.52e-3 53/60 (88.33%) ABL2;RAC2;ICAM1;...
Type I diabetes mellitus -1.96 0.00e+0 38/43 (88.37%) HLA-F;HLA-DOA;CD80;...
Antigen processing and presentation -1.99 0.00e+0 60/78 (76.92%) TAPBP;HLA-E;HSPA4;...
Autoimmune thyroid disease -2.01 0.00e+0 46/53 (86.79%) HLA-F;HLA-DOA;CD80;...
Systemic lupus erythematosus -2.11 0.00e+0 45/135 (33.33%) HLA-DOA;CD80;C8B;...
Allograft rejection -2.14 0.00e+0 32/38 (84.21%) HLA-F;HLA-DOA;CD80;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 3.33uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H